1Evaxion, in collaboration with the Gates Foundation, has developed novel AI-based polio vaccine design concepts using its AI-Immunology™ platform, which may be superior to existing vaccines.
2The company will present these polio vaccine concepts and data from its EVX-V1 cytomegalovirus (CMV) vaccine program at the World Vaccine Congress from March 31 to April 2, 2026.
3The polio vaccine concepts include hybrid capsid designs and de novo designed B-cell antigen approaches, aiming to combine the strongest aspects of existing vaccines.
4EVX-V1 is a next-generation, multi-component CMV vaccine program combining novel AI-discovered antigens with AI-optimized versions of established CMV vaccine antigens.
5The presentations will occur on April 1, 2026, for the polio vaccine and April 2, 2026, for the CMV vaccine, both in Room 202A at the World Vaccine Congress.